Clinical Trial Update: Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) [Phase 4]

View source ↗

Summary

A Phase 4 substudy update from a trial evaluating the accuracy of the ingestible event marker (IEM) detection by the MIND1 device; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Device Latency

Drugs mentioned

• Ingestible Event Marker (IEM)
• MIND1

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Device Latency | Phase 4 | Status: COMPLETED | Results posted: 2018-08-03